<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>60(1)</volume><submitter>Yaron Y</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>Prenatally detected central nervous system (CNS) anomalies present a diagnostic challenge. In this study, we compared the diagnostic yield of exome sequencing (ES) and chromosomal microarray analysis (CMA) in fetuses with a major CNS anomaly.&lt;h4>Methods&lt;/h4>This was a retrospective study of 114 cases referred for genetic evaluation following termination of pregnancy (TOP) due to a major CNS anomaly detected on prenatal ultrasound. All fetuses were first analyzed by CMA. All CMA-negative cases were offered ES. CMA-positive cases were reanalyzed using ES to assess its ability to detect copy-number variants (CNVs).&lt;h4>Results&lt;/h4>CMA identified a pathogenic or likely pathogenic (P/LP) CNV in 11/114 (10%) cases. Eighty-six CMA-negative cases were analyzed using ES, which detected P/LP sequence variants in 38/86 (44%). Among recurrent cases (i.e. cases with a previously affected pregnancy), the incidence of P/LP sequence variants was non-significantly higher compared with non-recurrent ones (12/19 (63%) vs 26/67 (39%); P = 0.06). Among the 38 cases with an ES diagnosis, 20 (53%) were inherited and carried a significant risk of recurrence. Reanalysis of 10 CMA-positive cases by ES demonstrated that the bioinformatics pipeline used for sequence variant analysis also detected all P/LP CNVs, as well as three previously known non-causative CNVs.&lt;h4>Conclusions&lt;/h4>In our study, ES provided a high diagnostic yield (> 50%) in fetuses with severe CNS structural anomalies, which may have been partly due to the highly selected case series that included post-TOP cases from a specialist referral center. These data suggest that ES may be considered as a first-tier test for the prenatal diagnosis of major fetal CNS anomalies, detecting both P/LP sequence variants and CNVs. This is of particular importance given the time constraints of an ongoing pregnancy and the risk of recurrence in future pregnancies. © 2022 The Authors. Ultrasound in Obstetrics &amp; Gynecology published by John Wiley &amp; Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.</pubmed_abstract><journal>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology</journal><pagination>59-67</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9328397</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Exome sequencing as first-tier test for fetuses with severe central nervous system structural anomalies.</pubmed_title><pmcid>PMC9328397</pmcid><pubmed_authors>Zunz Henig N</pubmed_authors><pubmed_authors>Marom D</pubmed_authors><pubmed_authors>Krajden Haratz K</pubmed_authors><pubmed_authors>Yaron Y</pubmed_authors><pubmed_authors>Reches A</pubmed_authors><pubmed_authors>Brabbing Goldstein D</pubmed_authors><pubmed_authors>Ben Sira L</pubmed_authors><pubmed_authors>Ofen Glassner V</pubmed_authors><pubmed_authors>Kurolap A</pubmed_authors><pubmed_authors>Baris Feldman H</pubmed_authors><pubmed_authors>Bar Shira A</pubmed_authors><pubmed_authors>Mory A</pubmed_authors><pubmed_authors>Malinger G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exome sequencing as first-tier test for fetuses with severe central nervous system structural anomalies.</name><description>&lt;h4>Objective&lt;/h4>Prenatally detected central nervous system (CNS) anomalies present a diagnostic challenge. In this study, we compared the diagnostic yield of exome sequencing (ES) and chromosomal microarray analysis (CMA) in fetuses with a major CNS anomaly.&lt;h4>Methods&lt;/h4>This was a retrospective study of 114 cases referred for genetic evaluation following termination of pregnancy (TOP) due to a major CNS anomaly detected on prenatal ultrasound. All fetuses were first analyzed by CMA. All CMA-negative cases were offered ES. CMA-positive cases were reanalyzed using ES to assess its ability to detect copy-number variants (CNVs).&lt;h4>Results&lt;/h4>CMA identified a pathogenic or likely pathogenic (P/LP) CNV in 11/114 (10%) cases. Eighty-six CMA-negative cases were analyzed using ES, which detected P/LP sequence variants in 38/86 (44%). Among recurrent cases (i.e. cases with a previously affected pregnancy), the incidence of P/LP sequence variants was non-significantly higher compared with non-recurrent ones (12/19 (63%) vs 26/67 (39%); P = 0.06). Among the 38 cases with an ES diagnosis, 20 (53%) were inherited and carried a significant risk of recurrence. Reanalysis of 10 CMA-positive cases by ES demonstrated that the bioinformatics pipeline used for sequence variant analysis also detected all P/LP CNVs, as well as three previously known non-causative CNVs.&lt;h4>Conclusions&lt;/h4>In our study, ES provided a high diagnostic yield (> 50%) in fetuses with severe CNS structural anomalies, which may have been partly due to the highly selected case series that included post-TOP cases from a specialist referral center. These data suggest that ES may be considered as a first-tier test for the prenatal diagnosis of major fetal CNS anomalies, detecting both P/LP sequence variants and CNVs. This is of particular importance given the time constraints of an ongoing pregnancy and the risk of recurrence in future pregnancies. © 2022 The Authors. Ultrasound in Obstetrics &amp; Gynecology published by John Wiley &amp; Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2026-05-09T19:30:26.96Z</modification><creation>2025-04-19T22:48:20.529Z</creation></dates><accession>S-EPMC9328397</accession><cross_references><pubmed>35229910</pubmed><doi>10.1002/uog.24885</doi></cross_references></HashMap>